Osemitamab clinical trials
Also written TST001.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2020
How each study uses osemitamab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- TST001
- 4
Studies by the year they started
4 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2020 | 2 |
| 2022 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 2
Transcenta Therapeutics (Hangzhou) Co., Ltd. (2) · Shanghai Zhongshan Hospital (1) · Henan Cancer Hospital (1)
Often tested with
Tested in the same studies.
Fidasimtamab (1) · Benmelstobart (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test osemitamab.
- Jun 2027A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid TumorsPhase 1/2 · Transcenta Therapeutics (Hangzhou) Co., Ltd.
- Jun 2027A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid TumorsPhase 1/2 · Transcenta Therapeutics (Hangzhou) Co., Ltd.
Studies
Open first, then newest update. How each study uses osemitamab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid TumorsActive, not recruitingPhase 1/2Transcenta Therapeutics (Hangzhou) Co., Ltd.NCT04495296Written as TST001
- A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid TumorsActive, not recruitingPhase 1/2Transcenta Therapeutics (Hangzhou) Co., Ltd.NCT04396821Written as TST001
- TST001 in Patients With CLDN18.2 Positive Previously Treated Advanced Biliary Tract CancerCompletedPhase 2Shanghai Zhongshan HospitalNCT05190575Written as TST001
- Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different GenotypesStatus unknownPhase 1/2Henan Cancer HospitalNCT05608785Written as TST001
Codes
What other systems call osemitamab · ClinicalTrials.gg INT016726
- UNII (FDA) H14V1A2F4DOSEMITAMABOne source FDA
- NCI Thesaurus C173726OsemitamabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | H14V1A2F4D | OSEMITAMAB | One source FDA |
| NCI Thesaurus | C173726 | Osemitamab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.